For people with heart disease already taking statins, adding this combo of niacin and laropiprant slightly raises the chance of nasty side effects like stomach problems, muscle pain, rashes, infections, and bleeding — about 1 extra case of infection for every 100 people over 4 years.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim reports precise absolute risk increases from a large, randomized controlled trial (e.g., HPS2-THRIVE), which is the only study design capable of measuring such specific, quantified adverse event differences. The use of absolute risk (not relative) and precise percentages with defined duration and population aligns with published trial results. The verbs 'increases' are appropriate because the data are derived from direct observation in a controlled trial with statistical significance.
More Accurate Statement
“In adults with atherosclerotic vascular disease on statin therapy, the addition of extended-release niacin (2 g/day) with laropiprant (40 mg/day) over a median follow-up of 3.9 years significantly increases the absolute risk of serious gastrointestinal adverse events by 1.0 percentage point, musculoskeletal adverse events by 0.7 percentage points, skin reactions by 0.3 percentage points, infections by 1.4 percentage points, and bleeding by 0.7 percentage points compared to placebo plus statin therapy.”
Context Details
Domain
medicine
Population
human
Subject
Adults with atherosclerotic vascular disease on statin therapy
Action
increases the absolute risk of
Target
serious gastrointestinal adverse events by 1.0 percentage point, musculoskeletal adverse events by 0.7 percentage points, skin reactions by 0.3 percentage points, infections by 1.4 percentage points, and bleeding by 0.7 percentage points
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Effects of extended-release niacin with laropiprant in high-risk patients.
This study gave people with heart disease niacin and laropiprant along with their statin pills, and found that they had slightly more stomach problems, muscle issues, skin reactions, infections, and bleeding compared to those who got a placebo — exactly as the claim says.